News

Indolent Lymphoma Standard Therapy Needs To Change: Bendamustine-Rituximab: Better Than CHOP-Rituximab+

7th June 2012

CHICAGO—The present-day standard CHOP-rituximab regimen for all indolent lymphomas has been overturned according to German investigators reporting here to the annual meeting of the American Society of Clinical Oncology. Professor Mathias Rummel of Giessen University gave Peter Goodwin his latest …

Read More+

Cetuximab Extends Survival In Advanced Non-Small Cell Lung Cancer+

16th March 2008

robert pirker Cetuximab Extends Survival In Advanced Non Small Cell Lung Cancer
Robert Pirker

ROBERT PIRKER , Medical University of Vienna
Phase III study results have detected improvements in overall survival among patients with advanced non-small cell lung cancer treated with a monoclonal antibody targeted to the epidermal growth factor receptor: EGFR.

Read More+

Lung Cancer Screening: Wait for Prospective Study Findings!+

16th March 2008

ugo pastorino Lung Cancer Screening: Wait for Prospective Study Findings!
Ugo Pastorino

UGO PASTORINO , Istituto Nazionale Tumori, Milan
Even the most sophisticated and powerful detection method for lung cancer detection, spiral CT, is still unproven in the context of mass screening for lung cancer. At the conference in Turin,

Read More+

Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma+

26th February 2008

martin dreyling Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma
Martin Dreyling

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
MARTIN DREYLING, University Hospital Grosshaden, Munich
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He

Read More+

Chronic Lymphocytic Leukemia After Fludarabine Failure+

26th February 2008

john gribben Chronic Lymphocytic Leukemia After Fludarabine Failure
John Gribben

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as

Read More+

Liver Cancer: Risk Groups for Screening+

27th January 2008

eugene schiff Liver Cancer: Risk Groups for Screening
Eugene Schiff

REFERENCE: General Session IV
EUGENE SCHIFF, University of Miami
Screening for Hepatitits C and B, and subsequent screening for cancer, can save millions of lives from hepatocellular carcinoma. Eugene Schiff told the Gastrointestinal Cancers Conference in Orlando which

Read More+

How to Prevent Stomach and Esophageal Cancers?+

26th January 2008

william blot How to Prevent Stomach and Esophageal Cancers?
William Blot

REFERENCE: General Session 1: Cancers of the Esophagus and Stomach
WILLIAM BLOT, Vanderbilt University, Nashville TN
Obesity emerged as a key cause of esophageal cancer from data presented by William Blot who told Peter Goodwin about the changing

Read More+

Early Breast Cancer Chemotherapy: Long Term Findings+

8th January 2008

richard peto Early Breast Cancer Chemotherapy: Long Term Findings
Richard Peto

REFERENCE: Lancet 371:29-40; January 5, 2008
RICHARD PETO, Oxford University
The prospect of cutting breast cancer mortality in half throughout the world is held out by Richard Peto of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). He

Read More+

AACR In New Partnership For San Antonio Breast Cancer Symposium+

14th December 2007

margaret foti AACR In New Partnership For San Antonio Breast Cancer Symposium
Margaret Foti

MARGARET FOTI, American Association for Cancer Research, Philadelphia
The San Antonio Breast Cancer Symposium will, in the future, be presented jointly by the Cancer Therapy and Research Center at the University of Texas Health Science Center, Baylor College

Read More+